Merkel Cell Carcinoma Pipeline Analysis 2018 (Q1) - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments - ResearchAndMarkets.com

DUBLIN--()--The "Merkel Cell Carcinoma Pipeline Analysis 2018 (Q1) - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments" report has been added to ResearchAndMarkets.com's offering.

Merkel Cell Carcinoma Pipeline Analysis report covers more than 10 drugs currently in different phases of development. Merkel cell Carcinoma also known as neuroendocrine carcinoma of the skin is a rare malignant cancer which appears as bluish or red coloured nodule generally on face, neck or head. Merkel cells are present at base of epidermis (outermost layer of skin) and are responsible for sense of touch. It is an aggressive form of cancer which tends to metastasize quickly. Exact cause of the cancer is still not known, however, excessive exposure to sunlight and weakened immune system may increase the risk of getting this cancer.

The report provides Merkel cell carcinoma treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Companies Mentioned

  • Millennium Pharmaceuticals Inc.
  • Amgen Inc
  • Apcure SAS
  • BeiGene Ltd
  • Bristol-Myers Squibb Co
  • Checkpoint Therapeutics Inc
  • Exelixis Inc
  • Immune Design Corp
  • NantKwest Inc
  • OncoSec Medical Inc
  • Philogen SpA
  • Tarveda Therapeutics Inc

Key Topics Covered:

1. Introduction

2. Disease Overview

3. Executive Summary

4. Market Dynamics

5. Pipeline Analysis/Outlook

6. Company profiling

For more information about this report visit https://www.researchandmarkets.com/research/wbmz5k/merkel_cell?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs, Clinical Trials, Skin Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs, Clinical Trials, Skin Cancer Drugs